A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

NCT05803421 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2749

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes
Obesity
Overweight or Obesity
Overweight
Cardiovascular Diseases
Chronic Kidney Disease

Interventions

DRUG: Orforglipron
DRUG: Insulin Glargine

Sponsor

Eli Lilly and Company